Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-12-24

Clinical Trial Update: Renal AL Amyloid Involvement and NEOD001 [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating NEOD001 for renal AL amyloidosis was terminated; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • NEOD001 (NEOD001)

Snippet

Sponsor: Tufts Medical Center | Conditions: Amyloidosis | Phase 2 | Status: TERMINATED | Results posted: 2019-12-24